Treating mast cell activation syndrome (MCAS) typically starts with two antihistamines taken together, one targeting skin and respiratory symptoms and another targeting gut symptoms, then builds from there based on your response. Because MCAS involves mast cells releasing an excess of chemical mediators throughout the body, treatment works in layers: blocking those mediators, stabilizing the mast cells themselves, avoiding triggers, and managing breakthrough reactions. Most people need a combination of approaches rather than a single fix.
Dual Antihistamines as the Foundation
The first step in MCAS treatment pairs an H1 antihistamine (the kind you’d take for allergies) with an H2 antihistamine (typically used for acid reflux). H1 blockers like cetirizine or fexofenadine address flushing, hives, itching, nasal congestion, and swelling. H2 blockers like famotidine target abdominal cramping, nausea, diarrhea, and acid reflux. Either type alone can reduce symptoms, but the combination tends to provide significantly better control than one or the other.
Second-generation H1 antihistamines (cetirizine, fexofenadine) are preferred over older options like diphenhydramine because they cause less drowsiness, making them easier to take consistently. Many people with MCAS need higher-than-standard doses, sometimes two to four times what’s on the box, so your prescriber will likely titrate upward based on your symptoms. It’s common to take these antihistamines daily as a preventive measure rather than only when symptoms flare.
Mast Cell Stabilizers
If antihistamines alone aren’t enough, the next layer targets the mast cells directly by preventing them from releasing their contents in the first place. Cromolyn sodium is the most commonly used option. For GI symptoms, the oral form is taken as a liquid solution four times daily, 30 minutes before meals and at bedtime. Adults typically start at 200 mg per dose. If symptoms haven’t improved after two to three weeks, the dose can be increased. Cromolyn works locally in the gut, so it’s particularly helpful for people whose primary symptoms are digestive.
Ketotifen is another mast cell stabilizer that also has antihistamine properties. It’s available as an eye drop over the counter, but the oral form (used for broader symptom control) often needs to be obtained through a compounding pharmacy. Ketotifen can cause drowsiness initially, so most people start at a low dose at bedtime and increase gradually.
Flavonoid Supplements
Quercetin, a plant-derived flavonoid, has shown genuine mast cell stabilizing effects in lab studies. It blocks the release of histamine and several inflammatory signaling molecules from mast cells, and one study found it was actually more effective than cromolyn at reducing certain inflammatory markers. A water-soluble form of quercetin at 2 grams per day reduced contact skin reactions by more than 50% in 8 out of 10 patients and completely eliminated the reaction in the other two. One practical advantage: quercetin appears to work preventively, meaning you take it before exposure to a trigger rather than during a reaction. It’s widely available as a supplement, though absorption varies between formulations.
Identifying and Managing Triggers
MCAS triggers extend far beyond food. Common physical and environmental triggers include temperature changes (especially heat), hot showers, strong fragrances, alcohol, stress, friction or pressure on the skin, and certain medications. Identifying your personal trigger profile is one of the most effective long-term strategies because avoidance prevents the cascade from starting in the first place.
For dietary triggers, a strict elimination diet isn’t usually the best starting point. Johns Hopkins recommends a more targeted approach: pick one or two foods you already associate with symptoms and remove them for two to four weeks, then assess. Foods commonly reported as problematic include aged or fermented items (aged cheese, kimchi, yogurt), alcohol (especially wine and beer), processed meats, citrus fruits, strawberries, tomatoes, spinach, chocolate, and leftovers that have been stored for more than a day or two. Histamine levels in food increase with time and fermentation, so freshness matters. That said, food triggers are highly individual, and many people with MCAS tolerate some “high histamine” foods without issue.
Keeping a symptom diary that tracks food, activities, environment, stress levels, and menstrual cycle (if applicable) can help you and your provider identify patterns that aren’t obvious at first.
Treatment for Refractory Cases
When standard antihistamines, mast cell stabilizers, and trigger avoidance aren’t providing adequate relief, omalizumab (a biologic injection originally developed for severe asthma and chronic hives) is the most studied next-step option. A systematic review of patients with refractory MCAS, defined as those who hadn’t responded to an H1 antihistamine plus at least one other treatment, found that 61% had a partial response to omalizumab and an additional group achieved complete resolution of symptoms. It was also effective at reducing anaphylaxis episodes and allowed some patients to stop systemic steroids. Complete responses were more common at doses of 300 mg per month or higher. The response didn’t depend on sex or whether the mast cell disease was clonal.
Other medications sometimes used in difficult cases include leukotriene blockers (which target a different inflammatory chemical released by mast cells), low-dose aspirin in select patients whose mast cells overproduce prostaglandins, and short courses of corticosteroids for severe flares. These are typically managed by a specialist, usually an allergist or immunologist with MCAS experience.
Preparing for Anaphylaxis
People with MCAS who have experienced anaphylaxis, or who are at risk for it, should carry epinephrine auto-injectors at all times. MCAS-related anaphylaxis can be triggered by things that wouldn’t cause anaphylaxis in most people: a hot day, a stressful event, exercise, or a combination of minor exposures that stack. The Mast Cell Disease Society recommends that epinephrine be administered intramuscularly and repeated at five-minute intervals up to three times if blood pressure remains low. One important detail: if you take a beta-blocker, epinephrine may not work the same way, and your emergency plan should account for this with an alternative protocol your doctor can outline in advance.
Many MCAS patients carry a written emergency protocol, sometimes on a card or bracelet, that explains their condition and its specific treatment needs to ER staff. This is especially useful because MCAS management in an emergency can differ from standard anaphylaxis protocols.
How Diagnosis Shapes Treatment
Formal MCAS diagnosis requires symptoms affecting two or more organ systems, a documented rise in mast cell mediators during a flare, and improvement with medications that block or stabilize mast cells. The most widely used lab marker is serum tryptase, measured during a symptomatic episode and compared to your personal baseline. The consensus formula considers a rise significant if the peak value exceeds 1.2 times your baseline plus 2 ng/mL. Because tryptase levels drop quickly, blood needs to be drawn within a few hours of symptom onset, which can be logistically difficult.
This diagnostic framework matters for treatment because it determines access to certain therapies, particularly biologics, and helps distinguish MCAS from other conditions with overlapping symptoms. If your tryptase doesn’t rise during flares (which happens in a subset of patients), 24-hour urine tests for histamine metabolites or prostaglandin markers can sometimes fill the gap.
Building a Treatment Stack
MCAS treatment is cumulative. Rather than switching from one medication to another, most patients add layers until their symptoms are manageable. A typical progression looks something like this:
- Layer 1: Daily H1 and H2 antihistamines, trigger identification and avoidance
- Layer 2: A mast cell stabilizer like cromolyn sodium, possibly quercetin supplementation
- Layer 3: Leukotriene blockers or other targeted medications for remaining symptoms
- Layer 4: Omalizumab or other biologic therapy for refractory disease
Responses vary widely between individuals, and a treatment that works well for one person may do nothing for another. Titrating medications slowly, changing one thing at a time, and tracking symptoms carefully gives you the clearest picture of what’s actually helping. Many people find that their treatment needs shift over time as triggers change or new sensitivities develop, so periodic reassessment with a knowledgeable provider is part of the long game.